|
Recommendations
|
BMO Capital analyst… BMO Capital analyst Simeon Siegel raised the firm's price target on American Eagle to $36 from $26 and keeps a Market Perform rating on the shares. The company's Q1 pre-announcement was "strong", reflecting its initiatives along with the "economic stimulus, renewed consumer optimism and pent-up demand," the analyst tells investors in a research note. The "trifecta" of tighter industrywide inventory, stronger consumer demand, and economic stimulus should carry forward for the company into Q2, Siegel adds. ShowHide Related Items >><< - 04/14/21
- American Eagle jumps about 7% to $35.21 after Q1 revenue guidance
- 03/04/21
- American Eagle rises 12.1%
- 03/03/21
- American Eagle CFO says Q1 revenue, op. income to exceed Q1 of 2019 and 2020
- 03/03/21
- American Eagle reinstates quarterly dividend at 13.75 per share
- 03/09/21 Morgan Stanley
- American Eagle price target raised to $25 from $18 at Morgan Stanley
- 03/04/21 B. Riley
- American Eagle price target raised to $32 from $30 at B. Riley Securities
- 03/04/21 Jefferies
- American Eagle price target raised to $32 after 'strong quarter' at Jefferies
- 03/04/21 UBS
- American Eagle price target raised to $37 from $31 at UBS
- 04/14/21
- American Eagle sees Q1 revenue on track over $1.0B, consensus $904.12M
- 03/03/21
- American Eagle Outfitters reports Q4 adjusted EPS 39c, consensus 36c
- 03/03/21
- Notable companies reporting after market close
- 01/21/21
- American Eagle sees Q4 revenue down low single digits, consensus $1.31B
- 11/05/20
- American Eagle partners with Disney for holiday collaboration, WWD reports
- 04/14/21
- Fly Intel: After-Hours Movers
- 03/03/21
- Fly Intel: After-Hours Movers
- 02/24/21
- Square, Workhorse downgrades among today's top calls on Wall Street
- 11/24/20
- Fly Intel: After-Hours Movers
- 03/25/21
- American Eagle put volume heavy and directionally bearish
- 12/29/20
- American Eagle call volume above normal and directionally bullish
- 11/24/20
- American Eagle options imply 10.4% move in share price post-earnings
- 10/29/20
- American Eagle put volume heavy and directionally bearish
|
|
Conference/Events
|
Annual Clinical Genetics… Annual Clinical Genetics Virtual Meeting of ACMG to be held on April 13-16. Webcast Link ShowHide Related Items >><< - 03/04/21
- X4 Pharmaceuticals expects cash to fund operations into 2022
- 02/02/21
- X4 Pharmaceuticals announces inducement grants under Nasdaq listing rule
- 12/14/20
- X4 Pharmaceuticals appoints Diego Cadavid as CMO
- 12/10/20
- X4 Pharmaceuticals receives Rare Pediatric Disease Designation for mavorixafor
- 02/10/21
- Under Armour says plans to return to profitability in 2021
- 12/04/20
- Virgin Galactic unveils spacesuits developed in partnership with Under Armour
- 12/01/20
- Under Armour announces creation and launch of Curry Brand
- 10/30/20
- Under Armour says has line of sight to deliver slightly positive EPS in 2021
TAK Takeda Pharmaceutical - 04/12/21
- Intellia Therapeutics appoints Georgia Keresty to board of directors
- 04/07/21
- Kamada announces amendment to GLASSIA license agreement with Takeda
- 03/31/21
- Takeda Pharmaceutical completes sale of OTC, non-core assets to Orifarm
- 04/12/21
- Sanofi to invest EUR 400M in vaccine production site in Singapore
- 04/12/21
- Jounce Therapeutics appoints Dmitri Wiederschain as Chief Scientific Officer
- 04/12/21
- C4XD enters licensing agreement with Sanofi for oral IL-17A inhibitor program
- 04/09/21
- Sanofi acquires Tidal Therapeutics for $160M upfront payment
- 04/14/21
- Ocugen appoints John Paul Gabriel as SVP, manufacturing and supply chain
- 04/05/21
- Ultragenyx, n-Lorem Foundation team on ultra-rare diseases treatment development
- 03/08/21
- Ultragenyx announces FDA clearance of IND application for UX053
- 02/17/21
- Ultragenyx announces approval of Dojolvi in Canada
- 04/05/21
- Invitae announces $1.15B investment supporting ongoing growth initiatives
- 04/05/21
- Invitae to acquire Genosity for approximately $200M
- 03/09/21
- Invitae rises 11.8%
- 03/08/21
- Invitae 'among most important companies' in molecular testing, ARK's Wood says
- 03/31/21
- Natera, Tesis to collaborate on prenatal genetic testing
- 03/24/21
- Natera: FDA grants two Breakthrough Device Designations for Signatera MRD test
- 03/10/21
- Natera and Genentech initiate Phase 3 trial of Signatera test
- 02/17/21
- Natera, Personalis partner for personalized oncology monitoring
- 03/30/21
- Illumina to oppose FTC's challenge of Grail acquisition
- 03/30/21
- Illumina down 5% after FTC challenges proposed acquisition of Grail
- 03/30/21
- FTC challenges Illumina's proposed acquisition of cancer detection test maker
- 03/30/21
- FTC challenges Illumina's proposed acquisition of Grail
- 03/01/21
- Amicus sees FY21 total Galafold revenue $300M-$315M
- 02/11/21
- Amicus AT-GAA not stat. significant for superiority vs. alglucosidasa alfa
- 02/11/21
- Amicus trading resumes
- 02/11/21
- Amicus trading halted, news pending
- 04/14/21
- Homology Medicines announces two presentations on phenylketonuria, MPS II
- 04/12/21
- Homology Medicines announces promotion of Tim Kelly to COO
- 04/12/21
- Homology Medicines announces promotion of Tim Kelly to COO
- 04/06/21
- Homology Medicines drops 8% to $8.51 after announcing $50M stock offering
- $127.31 /
-1.055 (-0.82%) - 04/01/21
- Iqvia acquires remaining interest in Q2 Solutions from Quest Diagnostics
- 04/01/21
- Quest Diagnostics sells minority stake in Q2 Solutions to IQVIA for $760M cash
- 03/15/21
- Zora Biosciences signs non-exclusive license agreement with Quest Diagnostics
- 03/08/21
- Quest Diagnostics to acquire outreach laboratory services business of Mercy
- 04/14/21
- Centogene extends partnership with Takeda Pharmaceutical
- 12/08/20
- Centogene, Alnylam launch joint clinical screening program
- 11/25/20
- Centogene expands partnership with PTC Therapeutics
- 10/20/20
- Centogene CEO Arndt Rolfs to step down, Andrin Oswald to succeed
- 04/14/21
- Bionano Genomics announces pre-clinical evaluation of OGM by FEC
- 04/07/21
- Bionano Genomics announces global expansion of adoption of its Saphyr system
- 04/06/21
- Bionano Genomics announces publication on optical genome mapping
- 03/03/21
- Bionano Genomics customer Praxis Genomics receives DEX Z-codes from Palmetto
APLT Applied Therapeutics - 02/01/21
- Applied Therapeutics restarts pediatric galactosemia study
- 12/09/20
- Applied Therapeutics launches Galactosemia awareness, education initiative
- 12/09/20
- Applied Therapeutics announces MRS data from ACTION-Galactosemia study
APLT Applied Therapeutics - 11/17/20 Barclays
- Applied Therapeutics price target lowered to $44 from $64 at Barclays
- 10/08/20 Truist
- Applied Therapeutics initiated with a Buy at Truist
- 10/08/20 Truist
- Applied Therapeutics initiated with a Buy at Truist
- 04/22/20
- Fly Intel: Top five analyst initiations
- 02/08/21 Oppenheimer
- Bionano Genomics price target raised to $15 from $1.50 at Oppenheimer
- 01/26/21 Ladenburg
- Bionano Genomics price target raised to $14 from $1.25 at Ladenburg
- 01/22/21 Maxim
- Bionano Genomics price target raised to $14 from $2 at Maxim
- 12/04/20 Roth Capital
- Bionano Genomics downgraded to Neutral from Buy at Roth Capital
- 11/05/20 Credit Suisse
- Centogene initiated with an Outperform at Credit Suisse
- 04/24/20 BTIG
- Centogene price target raised to $23 from $18 at BTIG
- 04/24/20 Evercore ISI
- Centogene downgraded to In Line from Outperform at Evercore ISI
- $127.31 /
-1.055 (-0.82%) - 03/12/21 Baird
- Quest Diagnostics downgraded to Neutral from Outperform at Baird
- 01/29/21 Citi
- Quest Diagnostics price target raised to $158 from $151 at Citi
- 12/17/20 Morgan Stanley
- Morgan Stanley cuts Quest Diagnostics to Equal Weight ahead of 2022 slowdown
- 12/17/20 Morgan Stanley
- Quest Diagnostics downgraded to Equal Weight from Overweight at Morgan Stanley
- 03/01/21 Stifel
- Homology Medicines initiated with a Hold at Stifel
- 03/01/21 Oppenheimer
- Homology Medicines loses potential source of upside, says Oppenheimer
- 12/14/20 H.C. Wainwright
- Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
- 11/08/20 Oppenheimer
- Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
- 04/14/21 Cantor Fitzgerald
- Amicus upgraded to Overweight from Neutral at Cantor Fitzgerald
- 04/13/21 Cantor Fitzgerald
- Amicus upgraded to Overweight from Neutral at Cantor Fitzgerald
- 03/01/21 Stifel
- Amicus initiated with a Hold at Stifel
- 02/12/21
- Fly Intel: Top five analyst downgrades
- 04/06/21 Wells Fargo
- Illumina price target raised to $330 from $300 at Wells Fargo
- 04/06/21 Canaccord
- Illumina price target raised to $460 from $445 at Canaccord
- 04/05/21 Evercore ISI
- Evercore upgrades Edwards to Outperform ahead of its 'best pipeline cycle'
- 03/31/21 Canaccord
- Canaccord upgrades Illumina, says worth owning with or without Grail
- 03/10/21 Piper Sandler
- Natera, Genentech start Phase 3 trial using Signatera, says Piper Sandler
- 02/26/21 Piper Sandler
- Natera price target raised to $150 from $127 at Piper Sandler
- 01/27/21 Truist
- Natera initiated with a Buy at Truist
- 01/19/21 BTIG
- Natera price target raised to $135 from $112 at BTIG
- 04/05/21 Oppenheimer
- Oppenheimer upgrades Invitae on valuation, sees potential high $50s stock
- 04/05/21 Oppenheimer
- Invitae upgraded to Outperform from Perform at Oppenheimer
- 02/18/21 Ladenburg
- Invitae upgraded to Buy with $58 price target at Ladenburg
- 02/18/21 Ladenburg
- Invitae upgraded to Buy from Neutral at Ladenburg
- 03/24/21 Stifel
- Stifel remains optimistic on GTX-102 and Ultragenyx ahead of 'important' update
- 03/01/21 Stifel
- Ultragenyx resumed with a Buy at Stifel
- 02/12/21 Wedbush
- Ultragenyx price target raised to $130 from $113 at Wedbush
- 02/12/21 Barclays
- Ultragenyx price target raised to $186 from $176 at Barclays
- 04/06/21 Barclays
- Sanofi price target raised to EUR 85 from EUR 80 at Barclays
- 02/23/21 BofA
- BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
- 02/10/21 Morgan Stanley
- Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
- 02/05/21 Piper Sandler
- Piper reiterates Overweight on Kymera after Sanofi capital markets day
TAK Takeda Pharmaceutical - 04/05/21
- Fly Intel: Top five analyst downgrades
- 04/05/21 Barclays
- Molecular Templates MT-3724 discontinuation shouldn't be surprise, says Barclays
- 04/05/21 Jefferies
- Takeda Pharmaceutical downgraded to Hold from Buy at Jefferies
- 03/03/21 RBC Capital
- Ovid downgraded to Sector Perform at RBC Capital after rally on Takeda deal
- 02/22/21 Williams Capital
- Under Armour initiated with a Hold at Williams Trading
- 02/19/21 Oppenheimer
- Opco upgrades Under Armour on potential return to 'outsized' sales growth
- 02/19/21 Oppenheimer
- Under Armour upgraded to Outperform from Perform at Oppenheimer
- 02/11/21 Jefferies
- Under Armour price target raised to $30 from $25 at Jefferies
- 12/17/20 Brookline
- X4 Pharmaceuticals initiated with a Buy at Brookline
- 12/14/20 Roth Capital
- New CMO 'another solid addition' to X4 Pharmaceuticals team, says Roth Capital
- 06/12/20 Roth Capital
- X4 Pharmaceuticals data boost confidence in Phase 3 study, says Roth Capital
- 03/04/21
- X4 Pharmaceuticals reports Q4 EPS (91c), consensus (90c)
- 11/05/20
- X4 Pharmaceuticals reports Q3 EPS (87c), consensus (76c)
- 02/10/21
- Under Armour sees Q1 EPS 3c, consensus (5c)
- 02/10/21
- Under Armour sees FY21 adjusted EPS 12c-14c, consensus 13c
- 02/10/21
- Under Armour reports Q4 adjusted EPS 12c, consensus (7c)
- 02/09/21
- Notable companies reporting before tomorrow's open
TAK Takeda Pharmaceutical - 04/05/21
- Molecular Templates to assume full rights of TAK-169 from Takeda
- 02/05/21
- Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year
- 10/29/20
- Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year
- 02/11/21
- Ultragenyx backs FY21 revenue guidance range for Crysvita
- 02/11/21
- Ultragenyx backs FY21 revenue guidance range for Crysvita
- 02/11/21
- Ultragenyx reports Q4 EPS (37c), consensus ($1.16)
- 10/27/20
- Ultragenyx reports Q3 EPS ($1.13), consensus ($1.27)
- 02/17/21
- Invitae sees FY21 revenue 'in excess of' $450M, consensus $488.37M
- 02/17/21
- Invitae reports Q4 adjusted EPS (63c), consensus (55c)
- 01/11/21
- Invitae sees FY21 revenue 'in excess of' $450M, consensus $513.7M
- 01/11/21
- Invitae reports preliminary FY20 revenue $278M+, consensus $274.93M
- 02/25/21
- Natera sees 2021 revenue $500M-$525M, consensus $469.31M
- 02/25/21
- Natera reports Q4 EPS (89c), consensus (62c)
- 11/05/20
- Natera sees 2020 revenue $380M-$390M, consensus $359.49M
- 11/05/20
- Natera reports Q3 EPS (72c), consensus (68c)
- 04/05/21
- Illumina sees FY21 revenue growth 25%-28%, consensus $3.91B
- 04/05/21
- Illumina sees Q1 revenue roughly $1.085B, consensus $924.6M
- 02/11/21
- Illumina sees FY21 adjusted EPS $5.10-$5.35, consensus $6.11
- 02/11/21
- Illumina reports Q4 adjusted EPS $1.22, consensus $1.11
- 03/01/21
- Amicus reports FY20 EPS ($1.07), consensus ($1.02)
- 11/05/20
- Amicus reports Q3 EPS (25c), consensus (22c)
- 03/11/21
- Homology Medicines reports Q4 EPS (62c), consensus (68c)
- 11/09/20
- Homology Medicines reports Q 3EPS (62c), consensus (80c)
- $127.31 /
-1.055 (-0.82%) - 04/01/21
- Iqvia raises FY21 EPS view to $7.89 -$8.20 from $7.77 - $8.08 , consensus $7.98
- 04/01/21
- Iqvia raises FY21 EPS view to $7.89 -$8.20 from $7.77 - $8.08 , consensus $7.98
- 03/11/21
- Quest Diagnostics backs first half adjusted EPS view $5.90-$6.90 at investor day
- 02/04/21
- Quest Diagnostics sees first half adjusted EPS $5.90-$6.90
- 12/16/20
- Centogene sees FY20 revenue over EUR100M
- 12/16/20
- Centogene reports Q3 revenue EUR36.3M vs. EUR11.6M a year ago.
- 10/20/20
- Centogene raises FY20 revenue view to over EUR 80M from EUR 60M-EUR 65M
- 03/23/21
- Bionano Genomics reports Q1 revenue $3.9M, consensus $3.5M
- 03/23/21
- Bionano Genomics reports Q1 revenue $3.9M, consensus $3.5M
- 11/12/20
- Bionano Genomics reports Q3 revenue $2.2M, consensus $2.07M.
- 10/15/20
- Bionano Genomics sees Q3 revenue $1.9M-$2.3M, consensus $2.07M
APLT Applied Therapeutics - 03/18/21
- Applied Therapeutics reports 2020 EPS ($4.28), consensus ($4.53)
- 11/12/20
- Applied Therapeutics reports Q3 EPS ($1.33), consensus ($1.02)
|